Blog

ADA 2026: The Obesity Drug Landscape Is Getting Crowded

The American Diabetes Association meeting delivered major data on retatrutide, CagriSema, and the next wave of obesity treatments. Here's what matters.

The American Diabetes Association’s annual scientific sessions wrapped up this week, and if there’s one takeaway from ADA 2026, it’s that the obesity treatment space is no longer a two-horse race between semaglutide and tirzepatide. The next generation of compounds delivered headline-grabbing data, and the competitive picture is more complex than most people expected.

Here’s what went down.

Retatrutide Stole the Show

Eli Lilly’s triple agonist retatrutide was the clear star of ADA 2026. The latest data showed weight loss of 28% at 80 weeks and 30% at 104 weeks at the highest dose in patients with obesity. Those numbers are genuinely remarkable - they represent a level of pharmacological weight loss that would have seemed implausible a decade ago.

Analysts at RBC Capital Markets were quick to christen Lilly the “clear winner from ADA,” with retatrutide getting special mention. The compound works on three receptor pathways simultaneously - GLP-1, GIP, and glucagon receptors - and the triple mechanism appears to deliver something beyond what the single and dual agonists can achieve.

For context, semaglutide (the active ingredient in Wegovy and Ozempic) typically produces around 15-17% weight loss in obesity trials, while tirzepatide (Mounjaro/Zepbound) lands in the 20-22% range. Retatrutide at 30% is operating in a different category entirely.

Novo Nordisk Says “Jury Still Out” on CagriSema

Novo Nordisk’s chief scientific officer Martin Holst Lange pushed back on the narrative that Lilly has already won the next-generation obesity race. In an interview on the sidelines of the conference, he told Fierce Biotech that Novo has “four assets in our clinical pipeline that look to be competitive with” retatrutide.

CagriSema, Novo’s combination of semaglutide and the amylin analogue cagrilintide, showed 23% average weight loss in its pivotal obesity studies. Lange admitted that’s “not competitive” with retatrutide’s ADA data, but argued the comparison isn’t straightforward.

“At some point it’s not about the weight loss anymore,” Lange said. While companies are now developing obesity assets that can “give ranges of weight loss,” factors like tolerability, comorbidity management, and quality of life will become increasingly important as the field matures.

He also pointed out that CagriSema has shown strong glycemic control in Type 2 diabetes - “actually better than what we saw from our competitors” - and that Novo is running a new trial designed to push CagriSema’s weight loss higher through dose adjustments and longer treatment durations.

Novo’s pipeline also includes zenagamtide, a unimolecular GLP-1 and amylin receptor agonist that showed 24% weight loss in Phase 2 obesity data and more than 14% weight loss in diabetes patients.

The New Contenders

Beyond the Lilly-Novo rivalry, ADA 2026 highlighted a wave of new entrants:

Pfizer’s berobenatide was described as a potential “foundational” obesity drug. Details are still emerging, but Pfizer is positioning it as a serious competitor in the space.

Roche’s enicepatide drew some “me-too” comparisons, but Roche is clearly betting that the obesity market is large enough to support multiple players with similar mechanisms.

AstraZeneca announced what BioPharma Dive described as an “extensive” obesity drug push, with newly published data convincing the company to build out a sprawling late-stage program for its oral GLP-1 pill. AstraZeneca’s entry into the obesity space is significant because they’re one of the few major pharma companies that had been sitting on the sidelines.

What This Means for Research Interest

The ADA 2026 data paints a picture of a field that’s advancing rapidly across multiple fronts simultaneously. We’re seeing:

  • Higher efficacy ceilings - retatrutide at 30% weight loss sets a new benchmark
  • Mechanism diversification - triple agonists, dual agonists, and novel combinations are all showing promise
  • Oral formulations gaining ground - AstraZeneca’s pill-form data suggests injections may not be the only game in town for long
  • A crowded pipeline - with this many compounds in late-stage development, the next 2-3 years will see significant competitive pressure

The research community is watching closely to see whether these compounds can maintain their efficacy over longer periods, what the safety profiles look like at scale, and whether the benefits extend beyond weight loss to the broader metabolic and cardiovascular improvements that have made GLP-1s so interesting.

What the Research Says

The data presented at ADA 2026 builds on a growing body of evidence that multi-receptor agonism can produce substantially greater weight loss than single-target approaches. The key question now shifts from “how much weight can you lose?” to “what’s the best balance of efficacy, tolerability, and comorbidity reduction?”

Cross-trial comparisons remain inherently limited - different patient populations, trial designs, and endpoints make direct head-to-head conclusions difficult. The real test will come from the dedicated comparator trials that several companies are now running.

Sources

Want to stay across the latest peptide research developments? Join the Grey Highway Telegram community for discussion and updates.

Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, therapeutic recommendations, or endorsements of any compound. Grey Highway is a research-education community. We do not sell, supply, or promote the use of research compounds. Always consult a qualified healthcare professional regarding health decisions. For Australian regulatory information, visit the TGA website.